Bayer's Fair Value Climbs to EUR 64 as Sunharbo Clearance Eases Pipeline Risk
Published on 11/18/2026 at 05:20 | Editorial boerse-global.deDZ Bank lifts price target on operational recovery, debt reduction and legal progress
DZ Bank raised its fair value estimate for Bayer from EUR 60 to EUR 64 on 5 November, keeping its "Buy" rating intact. Analyst Peter Spengler pointed to the group's operational stabilisation, its debt reduction and advances on US legal risks as the drivers behind the higher valuation.
The upgrade landed two days after Bayer reported a group net loss of EUR 672 million for the third quarter of 2026 — a headline figure that sat alongside a positive EBITDA before special items. Revenue in the reporting quarter reached EUR 10.1 billion, while EBITDA before special items came in at EUR 1.62 billion.
Should investors sell immediately? Or is it worth buying Bayer?
Guidance Raised on Three Fronts
Alongside the quarterly figures, Bayer lifted its outlook for the Pharmaceuticals margin and for free cash flow, and said it expected lower net financial debt. For full-year adjusted group EBITDA, the company raised its target to a range of EUR 9.8 billion to EUR 10.3 billion, up from a previous expectation of EUR 9.6 billion to EUR 10.1 billion.
FDA Green Light for Asundexian
A separate boost came from Washington, where the FDA approved the stroke drug Asundexian under the brand name Sunharbo. The clearance covers use in combination with an antiplatelet agent to reduce the risk of recurrent stroke in certain adults. According to Bayer, Asundexian is the first approved factor XIa inhibitor anywhere in the world. The company said shipments would begin between mid and late November.
Jefferies analyst Michael Leuchten wrote in the wake of the approval that the risk to Bayer's pharmaceutical pipeline had fallen considerably. dpa-AFX reported on 10 November that the clearance had given the stock additional momentum.
Shares Slip After Strong Run
The equity nonetheless lost ground yesterday, shedding 1.4% to close at EUR 56.02. Even so, Bayer shares remain up 51% since the start of the year.
Ad
Bayer Stock: New Analysis - 18 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
